Lee et al. (Lee et al. 2016) reported that ARID1A loss was significantly more prevalent in the MMR-deficient CRC cases than in the MMR-proficient CRC cases (18.7% vs 6.3%, P < 0.001). This evidence concerns the gene ARID1A and colorectal carcinoma.